ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ratutrelvir

Also written as “Ratutrelvir (83-0060) non-randomised”, “Ratutrelvir (83-0060)” and “83-0060”.

Its studies are mostly in COVID-19, led by Traws Pharma.

Furthest: phase 2, since Sep 3, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Traws Pharma20 open or runningphase 2since Sep 3, 2025May 2, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 2, 2024First study: phase 1 study in Healthy Volunteers OnlyFirst studyNCT06402136 · 57 enrolled · Australia
  2. Feb 13, 2025Named ratutrelvirINNProposed as its International Nonproprietary Name in WHO's List 132
  3. Sep 3, 2025Phase 2 study in COVID-19NCT07157007 · 93 enrolled · Uzbekistan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07157007COVID-19 · Uzbekistan2CompletedFeb 16, 202693
NCT06402136Healthy Volunteers Only · Australia1CompletedAug 9, 202457

How it is read

Names in the registry

  • “Ratutrelvir (83-0060) non-randomised”, 1 entry
  • “Ratutrelvir (83-0060)”, 1 entry
  • “83-0060”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.